Masoprocol lowers blood pressure in rats with fructose-induced hypertension.
Rats with fructose-induced hypertension were treated by oral gavage with either masoprocol (nordihydroguaiaretic acid) or vehicle. Masoprocol treatment resulted in significantly (P < .05 to .001) lower values for systolic blood pressure (120 +/- 3 v 164 +/- 5 mm Hg), as well as plasma insulin (30 +/- 5 v 44 +/- 4 microU/mL), free fatty acid (551 +/- 20 v 692 +/- 22 microEq/L), and triglyceride (79 +/- 5 v 219 +/- 32 mg/dL) concentrations. These results indicate that masoprocol, a lipoxygenase inhibitor, is able to lower blood pressure, as well as improve the metabolic abnormalities present in a rodent model of hypertension that simulates the characteristic of many patients with essential hypertension.
Gowri
M S
MS
Stanford University School of Medicine, California, USA.
Reaven
G M
GM
Azhar
S
S
D000284:Administration, Oral; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D004195:Disease Models, Animal; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005500:Follow-Up Studies; D005632:Fructose / Q000633:toxicity; D006973:Hypertension / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D007328:Insulin / Q000097:blood; D016859:Lipoxygenase Inhibitors / Q000008:administration & dosage*; D008297:Male; D009637:Masoprocol / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D005230:Fatty Acids, Nonesterified; D007328:Insulin; D016859:Lipoxygenase Inhibitors; D014280:Triglycerides; D005632:Fructose; D009637:Masoprocol